FDA Releases Guidance on Topical Patches
The agency publishes draft guidance on assessing the adhesion of transdermal delivery systems and topical patches.
On May 31, 2016, FDA issued draft guidance on recommendations for designing and performing studies to evaluate adhesive performance in transdermal delivery systems or topical patches submitted with an abbreviated new drug application (ANDA). The draft guidance addresses the agency’s thinking in regards to adhesion scoring systems; adhesion studies including study design, study conduct, and statistical analysis; adhesion and bioequivalence; and formatting data submission.
FDA states that the new draft guidance supersedes “recommendations related to adhesion studies provided in individual product-specific guidances published prior to the date of publication of this guidance.”
Source: FDA
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
